Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for 4 Weeks for the Treatment of Common Warts in Pediatric Subjects

NCT00116675 is registered in ClinicalTrials.gov with Graceway Pharmaceuticals, LLC as lead sponsor.

NCT NCT00116675
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00116675 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for 4 Weeks for the Treatment of Common Warts in Pediatric Subjects
Lead sponsor
Graceway Pharmaceuticals, LLC
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2005
Completion date
April 30, 2006
Enrollment
84
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

warts